Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial
帕博利珠单抗联合奥拉帕尼治疗既往接受过治疗且未经生物标志物筛选的转移性去势抵抗性前列腺癌患者：随机、开放标签、III期KEYLYNK-010试验
期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO.23.00233
Antonarakis, Emmanuel S; Park, Se Hoon; Goh, Jeffrey C; Shin, Sang Joon; Lee, Jae Lyun; Mehra, Niven; McDermott, Ray; Sala-Gonzalez, Núria; Fong, Peter C; Greil, Richard; Retz, Margitta; Sade, Juan Pablo; Yanez, Patricio; Huang, Yi-Hsiu; Begbie, Stephen D; Gafanov, Rustem Airatovich; De Santis, Maria; Rosenbaum, Eli; Kolinsky, Michael P; Rey, Felipe; Chiu, Kun-Yuan; Roubaud, Guilhem; Kramer, Gero; Sumitomo, Makoto; Massari, Francesco; Suzuki, Hiroyoshi; Qiu, Ping; Zhang, Jinchun; Kim, Jeri; Poehlein, Christian H; Yu, Evan Y
